絞り込み

16555

広告

Randomized Trial of Vonoprazan- Versus PPI-Based Third-Line Triple Therapy With Sitafloxacin for Helicobacter pylori.

著者 Sue S , Shibata W , Sasaki T , Kaneko H , Irie K , Kondo M , Maeda S
J Gastroenterol Hepatol.2018 Aug 27 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (25view , 0users)

Full Text Sources

This was a prospective, randomized trial of the efficacy of vonoprazan-based and proton-pump-inhibitor-based 7-day triple regimens with amoxicillin and sitafloxacin as a third-line therapy for eradicating Helicobacter pylori after failure of clarithromycin- and metronidazole-based first- and second-line therapy.
PMID: 30151994 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード